Evolving standards of care for neoadjuvant and adjuvant therapy in esophageal, gastroesophageal junction, and gastric cncer.
Clin Adv Hematol Oncol
; 19(12): 784-793, 2021 Dec.
Article
in En
| MEDLINE
| ID: mdl-34928934
ABSTRACT
Multimodality therapy, which can include systemic therapy, radiation therapy, and surgery, is the preferred approach for most localized, clinical T2 to T4, and/or node-positive esophageal, gastroesophageal junction, and gastric cancers. The optimal content and sequence of perioperative treatment of patients with different sites of disease and tumor histologic types continue to evolve. This review highlights the current standard-of-care approaches and areas of ongoing clinical research, including biomarker-directed therapy, pertaining to the treatment of esophageal, gastroesophageal junction, and gastric cancers in patients who are candidates for therapy with curative intent.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Stomach Neoplasms
/
Neoadjuvant Therapy
Type of study:
Guideline
Limits:
Humans
Language:
En
Journal:
Clin Adv Hematol Oncol
Journal subject:
HEMATOLOGIA
/
NEOPLASIAS
Year:
2021
Type:
Article